GT802

GT802 is an autologous chimeric antigen receptor (CAR) T-cell therapy targeting the CD19 antigen, currently under clinical investigation for the treatment of relapsing/refractory multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD). Developed by investigators at Tongji Hospital in collaboration with Wuhan Gene-Therapy Biopharmaceutical, GT802 is designed to deplete CD19-expressing B cells, which are key drivers of the inflammatory response and demyelination in these autoimmune central nervous system disorders. The therapy involves the genetic modification of a patient's own T cells to express a CAR that recognizes CD19, followed by re-infusion into the patient after lymphodepleting chemotherapy. Early clinical data suggest that GT802 may provide a potent and durable reduction in B-cell populations, potentially offering a new therapeutic option for patients who have not responded to conventional disease-modifying therapies.